HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation

Figure 2

HCV eradication with DAA does not significantly impact patient survival or HCC recurrence rates post-transplant. There was no difference in patient survival between HCV+/HCC LT patients who achieved SVR pre-transplant (blue line, N=13), HCV+/HCC LT patients who achieved SVR post-transplant (green line, N=12), pre-DAA era HCV+/HCC LT patients (purple line, N=70), and HCC (non-HCV) LT patients (yellow line, N=63) (panel (a)). There was no difference in rates of HCC recurrence between these four cohorts as well. Data were analyzed using the Kaplan-Meier method with log rank analysis.

(a)

(b)